BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35037559)

  • 1. Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Tahir F; Sy J; Reddel S; Trotman J
    Leuk Lymphoma; 2022 Jun; 63(6):1464-1468. PubMed ID: 35037559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
    Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
    Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive Multifocal Leukoencephalopathy Among Ibrutinib Treatment In Chronic Lymphocytic Leukemia.
    Çetintepe T; Gediz F; Akyar I; Çetintepe L; Koç AM
    J Oncol Pharm Pract; 2022 Jul; 28(5):1249-1253. PubMed ID: 35037793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.
    Hsiehchen D; Arasaratnam R; Raj K; Froehlich T; Anderson L
    Oncology; 2018; 95(5):319-322. PubMed ID: 30045034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
    Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
    Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
    [No Abstract]   [Full Text] [Related]  

  • 8. Screening and monitoring of the BTK
    Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
    Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progressive multifocal leukoencephalopathy an chronic lymphocytic leukemia].
    Attout H; Rahmeh F; Lehuede G; Girardel M; Ziegler F
    Rev Med Interne; 2000 Aug; 21(8):698-700. PubMed ID: 10989496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progressive multifocal leukoencephalopathy (PML) in chronic lymphatic leukemia (CLL). Review of the literature and case report].
    Holzapfel C; Kellinghaus C; Lüttmann R; Zühlsdorf M; Burstedde V; Freund M; Husstedt IW
    Nervenarzt; 2002 Jun; 73(6):543-7. PubMed ID: 12243002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus.
    Ramadhani P; Bramantono B; Sedana MP
    Acta Med Indones; 2018 Apr; 50(2):151-158. PubMed ID: 29950535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature.
    D'Souza A; Wilson J; Mukherjee S; Jaiyesimi I
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E1-9. PubMed ID: 20223720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive multifocal leukoencephalopathy--a case report and review of the literature.
    Smolle E; Trojan A; Schuster SJ; Haybaeck J
    In Vivo; 2014; 28(5):941-8. PubMed ID: 25189911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy in a patient with B-cell chronic lymphocytic leukemia after COVID-19 vaccination, complicated with COVID-19 and mucormycosis: a case report.
    Amirifard H; Shahbazi M; Farahmand G; Ranjbar Z; Kaeedi M; Heydari Havadaragh S
    BMC Neurol; 2024 May; 24(1):151. PubMed ID: 38704555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
    Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
    J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progressive multifocal leukoencephalopathy in a female patient with chronic lymphatic leukemia].
    Heikens J; van Berkel W; de Vos RA; van der Avoort HG; Krul MR
    Ned Tijdschr Geneeskd; 1992 Feb; 136(5):232-5. PubMed ID: 1310527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine.
    Saumoy M; Castells G; Escoda L; Marés R; Richart C; Ugarriza A
    Leuk Lymphoma; 2002 Feb; 43(2):433-6. PubMed ID: 11999583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.